BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35404422)

  • 1. A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies.
    Corton JC; Mitchell CA; Auerbach S; Bushel P; Ellinger-Ziegelbauer H; Escobar PA; Froetschl R; Harrill AH; Johnson K; Klaunig JE; Pandiri AR; Podtelezhnikov AA; Rager JE; Tanis KQ; van der Laan JW; Vespa A; Yauk CL; Pettit SD; Sistare FD
    Toxicol Sci; 2022 Jun; 188(1):4-16. PubMed ID: 35404422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a mechanism-based approach for the prediction of nongenotoxic carcinogenic potential of agrochemicals.
    Heusinkveld H; Braakhuis H; Gommans R; Botham P; Corvaro M; van der Laan JW; Lewis D; Madia F; Manou I; Schorsch F; Wolterink G; Woutersen R; Corvi R; Mehta J; Luijten M
    Crit Rev Toxicol; 2020 Oct; 50(9):725-739. PubMed ID: 33236972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods.
    Waters MD; Jackson M; Lea I
    Mutat Res; 2010 Dec; 705(3):184-200. PubMed ID: 20399889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards achieving a modern science-based paradigm for agrochemical carcinogenicity assessment.
    Hilton GM; Corvi R; Luijten M; Mehta J; Wolf DC
    Regul Toxicol Pharmacol; 2023 Jan; 137():105301. PubMed ID: 36436696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing chemical carcinogenicity: hazard identification, classification, and risk assessment. Insight from a Toxicology Forum state-of-the-science workshop.
    Felter SP; Bhat VS; Botham PA; Bussard DA; Casey W; Hayes AW; Hilton GM; Magurany KA; Sauer UG; Ohanian EV
    Crit Rev Toxicol; 2021 Sep; 51(8):653-694. PubMed ID: 35239444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2-year rodent bioassay in drug and chemical carcinogenicity testing: Performance, utility, and configuration for cancer hazard identification.
    Suarez-Torres JD; Orozco CA; Ciangherotti CE
    J Pharmacol Toxicol Methods; 2021; 110():107070. PubMed ID: 33905862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sector call to improve carcinogenicity risk assessment through use of genomic methodologies.
    Yauk CL; Harrill AH; Ellinger-Ziegelbauer H; van der Laan JW; Moggs J; Froetschl R; Sistare F; Pettit S
    Regul Toxicol Pharmacol; 2020 Feb; 110():104526. PubMed ID: 31726190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the TD50 99 % CI for single dose rodent carcinogenicity studies.
    Thomas R; Oliveira AAF; Ponting DJ; Thresher A
    Toxicol Lett; 2023 Dec; 390():1-4. PubMed ID: 37923025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity.
    Ellinger-Ziegelbauer H; Aubrecht J; Kleinjans JC; Ahr HJ
    Toxicol Lett; 2009 Apr; 186(1):36-44. PubMed ID: 18822359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is current risk assessment of non-genotoxic carcinogens protective?
    Braakhuis HM; Slob W; Olthof ED; Wolterink G; Zwart EP; Gremmer ER; Rorije E; van Benthem J; Woutersen R; van der Laan JW; Luijten M
    Crit Rev Toxicol; 2018 Jul; 48(6):500-511. PubMed ID: 29745287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis.
    Kleinstreuer NC; Dix DJ; Houck KA; Kavlock RJ; Knudsen TB; Martin MT; Paul KB; Reif DM; Crofton KM; Hamilton K; Hunter R; Shah I; Judson RS
    Toxicol Sci; 2013 Jan; 131(1):40-55. PubMed ID: 23024176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action.
    Gusenleitner D; Auerbach SS; Melia T; Gómez HF; Sherr DH; Monti S
    PLoS One; 2014; 9(7):e102579. PubMed ID: 25058030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rethinking chronic toxicity and carcinogenicity assessment for agrochemicals project (ReCAAP): A reporting framework to support a weight of evidence safety assessment without long-term rodent bioassays.
    Hilton GM; Adcock C; Akerman G; Baldassari J; Battalora M; Casey W; Clippinger AJ; Cope R; Goetz A; Hayes AW; Papineni S; Peffer RC; Ramsingh D; Williamson Riffle B; Sanches da Rocha M; Ryan N; Scollon E; Visconti N; Wolf DC; Yan Z; Lowit A
    Regul Toxicol Pharmacol; 2022 Jun; 131():105160. PubMed ID: 35311659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of specific mRNA signatures as fingerprints for carcinogenesis in mice induced by genotoxic and nongenotoxic hepatocarcinogens.
    Kossler N; Matheis KA; Ostenfeldt N; Bach Toft D; Dhalluin S; Deschl U; Kalkuhl A
    Toxicol Sci; 2015 Feb; 143(2):277-95. PubMed ID: 25410580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of chemical structure on the extent and sites of carcinogenesis for 522 rodent carcinogens and 55 different human carcinogen exposures.
    Ashby J; Paton D
    Mutat Res; 1993 Mar; 286(1):3-74. PubMed ID: 7678908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of short-term tests in determining the genotoxicity or nongenotoxicity of chemicals.
    Ashby J
    IARC Sci Publ; 1992; (116):135-64. PubMed ID: 1428079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse outcome pathway-driven identification of rat liver tumorigens in short-term assays.
    Rooney J; Hill T; Qin C; Sistare FD; Corton JC
    Toxicol Appl Pharmacol; 2018 Oct; 356():99-113. PubMed ID: 30048669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.